Statistical Programming
Statistical Programming
Optimize your clinical studies with fully customised regulatory submission-ready analysis datasets and Tables, Listings, and Figures (TLFs) through our team of R and SaS programmers with over 15 years of industry experience, trained in ICH/GCP and CFR PART 11 regulations, and equipped with globally accepted tools and resources.
Our Statistical Programming Team provides services in:
- CDISC,SEND, SDTM & ADaM standards compliant datasets development and quality control.
- Tables, Listings, and Figures Generation.
- Interim Analysis support
- Ad- Hoc Analysis
- Rescue Studies
- PK/PD Programming
- Bioresearch Monitoring Support
CDISC Services
Raw and analysis data from clinicals trials has to be submitted in SEND, SDTM & ADaM standards-compliant model for FDA approval. We are registered CDISC solutions providers capable of processing your raw data to fit the FDA norms.
Our CDISC Services Include:
- Migrating study database to SEND, SDTM & ADaM standards-compliant model.
- Seamless processing in a short time span
- Perfect submission ready package
- Guaranteed data traceablity back to its original roots
TFL Generation
Generation and validation of Statistical data sets and TFLs are mandatory for a presentable statistical plan. Our Statisticians trained in ICH/GCP and Clinical SAS/R Programming fundamentals help you generate TFLs for your study.
Our TFL Generation services cover:
- Generation and validation of Statistical data sets and tables/listings/figures based on the parameters mentioned in the Protocol.
- Quality check procedure for generated data.
- Constantly updated feedback on our analyses.
CONTACT US
BIMO
This FDA authorized program demands a set of criteria in the pre-approval process of new medicines, devices and additives in the US market. Our team makes sure that your product/study checks all the requirements demanded by the system by having the following listings in place:
The listings include:
- Consented subjects
- Treatment assignment
- Discontinuations
- Study population
- Inclusion and exclusion criteria
- Adverse events
- Efficacy endpoints
- Concomitant medications
- Safety monitoring